Vinpocetine attenuates thioacetamide-induced liver fibrosis in rats

• Published in: Human & experimental toxicology 2021-02, Vol.40 (2), p.355-368
• Main Authors: Elnfarawy, Ahmed A, Nashy, Asmaa E, Abozaid, Alaa M, Komber, Ibrahim F, Elweshahy, Rawan H, Abdelrahman, Rehab S
• Format: Article
• Language: English
• Subjects: Alkaloids; Angiogenesis; Animals; Bile; Fibrosis; Glutathione - metabolism; Hydroxyproline; Inflammation; Interleukin 6; Interleukin-6 - metabolism; Liver; Liver - drug effects; Liver - metabolism; Liver - pathology; Liver Cirrhosis - chemically induced; Liver Cirrhosis - drug therapy; Liver Cirrhosis - metabolism; Liver Cirrhosis - pathology; Male; Malondialdehyde - metabolism; Morbidity; Nitric Oxide - metabolism; Oxidative stress; Oxidative Stress - drug effects; Protective Agents - pharmacology; Protective Agents - therapeutic use; Rats; Rats, Sprague-Dawley; Superoxide Dismutase - metabolism; Thioacetamide; Tumor Necrosis Factor-alpha - metabolism; Tumor necrosis factor-α; Vascular endothelial growth factor; Vinca Alkaloids - pharmacology; Vinca Alkaloids - therapeutic use; Vinpocetine
• ISSN: 0960-3271; 1477-0903
• DOI: 10.1177/0960327120947453

Liver fibrosis is associated with increased mortality and morbidity. However, there is not effective treatment so far. Vinpocetine (Vinpo) is a synthetic derivative of vinca alkaloid vincamine. Limited previous reports have shown some beneficial effects of Vinpo in different organ fibrosis, but the ability of Vinpo to inhibit liver fibrosis induced by thioacetamide (TAA) has not been reported, that is why we investigate the potential ability of this vinca alkaloid derivative to attenuate liver fibrosis. Hepatic fibrosis was induced in male Sprague Dawley rats by TAA (200 mg/kg; ip; 3 times/week) for 6 weeks. Daily treatments with Vinpo (10–20 mg/kg/day; orally) ameliorated TAA-induced hepatic oxidative stress and histopathological damage as indicated by a decrease in liver injury markers, LDH, hepatic MDA, and NOx levels, as well as increase anti-oxidative parameters. Besides, the anti-fibrotic efficacy of Vinpo was confirmed by decreasing hydroxyproline, and α-SMA. Also, the anti-inflammatory effect of Vinpo was explored by decreasing IL-6 and TNF-α levels. Our novel findings were that Vinpo decreased VEGF/Ki-67 expression in the liver confirming its effect on angiogenesis and proliferation. These findings reveal the anti-fibrotic effect of Vinpo against TAA-induced liver fibrosis in rats, and suggest the modulation of oxidative stress, inflammation, angiogenesis and proliferation as mechanistic cassette underlines this effect.